8 / 64
8
Overview
|
Friday, 25 September 2015
Room
Time
Cambridge
2nd Floor
Oxford
2nd Floor
Harvard
1st Floor
Stanford
1st Floor
Princeton
1st Floor
Foyer
Ground floor
08:30
–
10:00
S-13
Neuroimaging
approaches to
understanding
negative
symptoms
S-14
Modulating neu-
ral plasticity for
the treatment of
schizophrenia
S-15
Depressive
episodes in the
course of schizo-
phrenia-spectrum
disorders: clinical
challenges, thera-
peutic strategies
S-16
Clozapine: the
art of prescribing
S-17
Bridging animal-
human NMDAR
models of schizo-
phrenia through
EEG biomarkers
in behaving ro-
dents and humans
Registration Counter
Opening Hours: 08:00 – 18:30
Coffee Break
10:30
–
12:00
S-18
Impact of nega-
tive symptoms
on schizophre-
nia functional
outcome
S-19
Verbal and non-
verbal communi-
cation deficits in
schizophrenia
S-20
Psychological
treatments for
posttraumatic
stress disorder in
psychosis: feasi-
bility, safety and
efficacy
D-02
Should “schizo-
phrenia” be
renamed?
S-21
Neuroinflamma-
tion and infection
in schizophrenia
12:15
–
13:00
PL-02
Perspectives of
drug development
for the treatment
of schizophrenia
Broadcasting
of Plenary P-02
in room Oxford
13:00
-
14:30
Lunch Break
13:30 – 14:30
e
Guided Poster Sessions
l
Event Area, Ground Floor: P-06, P-09, P-10
l
Foyer, 2nd Floor: P-07
l
Sorbonne 2, 2nd Floor: P-08
14:30
-
16:00
S-22
Symptom dimen-
sions and their
clinical implica-
tion in schizo-
phrenia
S-23
Lifespan develop-
ment of schizo-
phrenia and how
the treatments
improve it
S-24
Improving out-
comes: factors
influencing help
seeking behavior,
duration of un-
treated psychosis
and treatment
outcome...
S-25
Detecting psy-
chosis proneness:
schizotypy and
clinical high risk
S-26
Disturbed con-
nectivity in
schizophrenia:
from dysfunc-
tional white mat-
ter tracts to mo
lecular findings
Coffee Break
16:30
–
18:00
S-27
The role of
psychotherapy in
the treatment of
schizophrenia
S-28
Assessment of
negative symp-
toms: challenges
and recent devel-
opments
S-29
Paranoia as
a symptom
dimension in
schizophrenia
S-30
Predicting Psy-
chosis - Method-
ological concepts
and first findings
of the ‘PRONIA‘
project
O-03
Drug treatment
Break
18:15
–
19:45
S-31
Avolition and
asociality: brid
ging gaps be-
tween animal and
human research
S-32
Social cognition
in schizophre-
nia - new task
developments and
establishing
paradigms
S-33
Schizophrenia as
neurodevelop-
mental disorder
and effects of
antipsychotic
treatment: new
insights from
animal models
O-04
Comorbidity